A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. 1985

A Rhedda, and J McCans, and A R Willan, and P M Ford

We report the results of a double blind placebo controlled crossover randomized study of the calcium channel blocking agent diltiazem in the treatment of Raynaud's phenomenon. Our results showed a significant reduction in both frequency and duration of attacks of vasospasm in the hands. There was no detectable difference in response between patients with primary and those with secondary Raynaud's phenomenon. Our study supports the use of calcium channel blocking agents in the treatment of intermittent digital vasospasm.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011928 Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress. Cold Fingers, Hereditary,Raynaud Phenomenon,Raynaud's Disease,Raynauds Disease
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A Rhedda, and J McCans, and A R Willan, and P M Ford
December 1991, Journal of cardiovascular pharmacology,
A Rhedda, and J McCans, and A R Willan, and P M Ford
August 1986, Clinical pharmacology and therapeutics,
A Rhedda, and J McCans, and A R Willan, and P M Ford
October 2009, The Journal of rheumatology,
A Rhedda, and J McCans, and A R Willan, and P M Ford
January 1985, Annals of the rheumatic diseases,
A Rhedda, and J McCans, and A R Willan, and P M Ford
January 1985, The Canadian journal of cardiology,
A Rhedda, and J McCans, and A R Willan, and P M Ford
September 2021, International clinical psychopharmacology,
A Rhedda, and J McCans, and A R Willan, and P M Ford
August 2000, The Journal of rheumatology,
A Rhedda, and J McCans, and A R Willan, and P M Ford
January 2009, Modern rheumatology,
A Rhedda, and J McCans, and A R Willan, and P M Ford
July 1988, Klinische Wochenschrift,
Copied contents to your clipboard!